Tag Archives: CLL

Findings also show how an experimental monoclonal antibody treatment inhibits growth and spread of cancer —

Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the most common form of blood cancer in adults.

They note, however, that these effects of Wnt5a were blocked by a humanized monoclonal antibody specific for ROR1, called cirmtuzumab (or UC-961), which inhibited the growth and spread of CLL cells in both cell lines and mouse models of leukemia. The findings are published in the December 21, 2015 issue of The Journal of Clinical Investigation. … Read the full story from the UC San Diego Newsroom

An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine in a study published in the Nov. 17 online early edition of the Proceedings of the National Academy of Sciences (PNAS).

The findings extend the anti-cancer potential of an experimental monoclonal antibody called cirmtuzumab, developed at UC San Diego Moores Cancer Center by Thomas Kipps, MD, PhD, and colleagues. Cirmtuzumab is currently in a first-in-human phase 1 clinical trial to assess its safety and efficacy in treating CLL. … Read the full story from the UC San Diego Newsroom

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. … Read the full story from the UC San Diego Newsroom

The Leukemia & Lymphoma Society has awarded Thomas J. Kipps, MD, PhD, Distinguished Professor of Medicine at the University of California, San Diego School of Medicine, with a 5-year, $6.25 million Specialized Center of Research program grant to support research on chronic lymphocytic leukemia (CLL), the most common adult leukemia in the United States. … Read the full story from the UC San Diego News Center

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells…. Read the full story from the UCSD Newsroom

Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, is principal investigator of the study, which was reported in the Proceedings of the National Academy of Sciences.

An international consortium of scientists studying chronic lymphocytic leukemia (CLL), based at the University of California, San Diego School of Medicine, has been awarded a 5-year, $20 million grant by the National Cancer Institute, part of the National Institutes of Health. The grant is the second renewal of funding for a broad-based effort designed to better understand the pathology of CLL – the most common form of leukemia in the Western world – and develop new drugs and treatments. … Read the full story from the UCSD Newsroom

Its goal is to evaluate the clinical and pre-clinical activity of Ad-ISF35, a replication-defective adenovirus vector that encodes a chimeric (human-mouse) CD154 molecule. The Ad-ISF35 is employed to transduce cancer cells and induce anti-tumor responses.

Dr. Castro and his coworkers have conducted a promising preliminary Phase 1 clinical study of Ad-ISF35 in six patients. Recently, they reported some of their findings in the Proceedings of the National Academy of Sciences (PNAS).Read the PNAS article